A double blind comparison of thiothixene and a trifluoperazine/chlorpromazine composite in the treatment of chronic schizophrenia.
Thirty chronic schizophrenic patients participated in a double-blind crossover trial of thiothixene (Navane) and a control drug combination of trifluoperazine and chlorpromazine. No statistically significant difference was found between the two drug conditions on numerous behavioural scales. Experience with thiothixene suggested that it was comparable with control drugs in the activation of withdrawn patients but needs to be used in combination with a more sedative antipsychotic agent in the treatment of some paranoid patients.
D002746:Chlorpromazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013888:Thiothixene / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014268:Trifluoperazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D014268:Trifluoperazine; D013888:Thiothixene; D002746:Chlorpromazine